Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 440

1.

Predicting Fluoropyrimidine-Related Toxicity: Turning Wish to Will, The Pamm-Eortc Position.

Ciccolini J, Del Re M, Danesi R, Milano G, Schellens JHM, Raymond E.

Ann Oncol. 2018 Jul 18. doi: 10.1093/annonc/mdy258. [Epub ahead of print] No abstract available.

PMID:
30032203
2.

Efficacy and Safety of Sunitinib in Patients With Well-Differentiated Pancreatic Neuroendocrine Tumours.

Raymond E, Kulke M, Qin SK, Yu X, Schenker M, Cubillo A, Lou W, Tomasek J, Thiis-Evensen E, Xu JM, Croitoru A, Khasraw M, Sedlackova E, Borbath I, Ruff P, Oberstein P, Ito T, Jia L, Hammel P, Shen L, Shrikhande SV, Shen Y, Sufliarsky J, Khan G, Morizane C, Galdy S, Khosravan R, Fernandez K, Rosbrook B, Fazio N.

Neuroendocrinology. 2018 Jul 10. doi: 10.1159/000491999. [Epub ahead of print]

PMID:
29991024
3.

Workloads of Competitive Surfing: Work-to-Relief Ratios, Surf-Break Demands, and Updated Analysis.

Farley ORL, Secomb JL, Raymond ER, Lundgren LE, Ferrier BK, Abbiss CR, Sheppard JM.

J Strength Cond Res. 2018 Jun 14. doi: 10.1519/JSC.0000000000002659. [Epub ahead of print]

PMID:
29912078
4.

Morphomic Malnutrition Score: A Standardized Screening Tool for Severe Malnutrition in Adults.

Lee C, Raymond E, Derstine BA, Glazer JM, Goulson R, Rajasekaran A, Cherry-Bukowiec J, Su GL, Wang SC.

JPEN J Parenter Enteral Nutr. 2018 May 22. doi: 10.1002/jpen.1175. [Epub ahead of print]

PMID:
29786877
5.

Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer.

Van Cutsem E, Hidalgo M, Canon JL, Macarulla T, Bazin I, Poddubskaya E, Manojlovic N, Radenkovic D, Verslype C, Raymond E, Cubillo A, Schueler A, Zhao C, Hammel P.

Int J Cancer. 2018 May 14. doi: 10.1002/ijc.31603. [Epub ahead of print]

PMID:
29756206
6.

A direct-to-patient telemedicine abortion service in Australia: Retrospective analysis of the first 18 months.

Hyland P, Raymond EG, Chong E.

Aust N Z J Obstet Gynaecol. 2018 Jun;58(3):335-340. doi: 10.1111/ajo.12800. Epub 2018 Mar 30.

PMID:
29603139
7.

Low-sensitivity urine pregnancy testing to assess medical abortion outcome: A systematic review.

Raymond EG, Shochet T, Bracken H.

Contraception. 2018 Jul;98(1):30-35. doi: 10.1016/j.contraception.2018.03.013. Epub 2018 Mar 10. Review.

PMID:
29534996
8.

Clinical and Biomarker Evaluations of Sunitinib in Patients with Grade 3 Digestive Neuroendocrine Neoplasms.

Pellat A, Dreyer C, Couffignal C, Walter T, Lombard-Bohas C, Niccoli P, Seitz JF, Hentic O, André T, Coriat R, Faivre S, Zappa M, Ruszniewski P, Pote N, Couvelard A, Raymond E.

Neuroendocrinology. 2018;107(1):24-31. doi: 10.1159/000487237. Epub 2018 Mar 8.

PMID:
29518779
9.

Self-assessment of medical abortion outcome using symptoms and home pregnancy testing.

Raymond EG, Tan YL, Grant M, Benavides E, Reis M, Sacks DN, Hannum C, Frapp S, Weaver MA.

Contraception. 2018 Apr;97(4):324-328. doi: 10.1016/j.contraception.2017.12.004. Epub 2017 Dec 11.

PMID:
29242085
10.

E3 Ubiquitin Ligase RNF125 Activates Interleukin-36 Receptor Signaling and Contributes to Its Turnover.

Saha SS, Caviness G, Yi G, Raymond EL, Mbow ML, Kao CC.

J Innate Immun. 2018;10(1):56-69. doi: 10.1159/000481210. Epub 2017 Nov 25.

PMID:
29176319
11.

Simplified medical abortion screening: a demonstration project.

Raymond EG, Tan YL, Comendant R, Sagaidac I, Hodorogea S, Grant M, Sanhueza P, Van Pratt E, Gillespie G, Boraas C, Weaver MA, Platais I, Bousieguez M, Winikoff B.

Contraception. 2018 Apr;97(4):292-296. doi: 10.1016/j.contraception.2017.11.005. Epub 2017 Nov 21.

PMID:
29170088
12.

Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response.

Lamarca A, Barriuso J, Kulke M, Borbath I, Lenz HJ, Raoul JL, Meropol NJ, Lombard-Bohas C, Posey J, Faivre S, Raymond E, Valle JW.

Br J Cancer. 2018 Jan;118(2):181-188. doi: 10.1038/bjc.2017.402. Epub 2017 Nov 21.

13.

Prognostic value of c-MET in head and neck cancer: A systematic review and meta-analysis of aggregate data.

Szturz P, Budíková M, Vermorken JB, Horová I, Gál B, Raymond E, de Gramont A, Faivre S.

Oral Oncol. 2017 Nov;74:68-76. doi: 10.1016/j.oraloncology.2017.09.009. Epub 2017 Sep 27. Review.

PMID:
29103754
14.

Exploring the feasibility of obtaining mifepristone and misoprostol from the internet.

Murtagh C, Wells E, Raymond EG, Coeytaux F, Winikoff B.

Contraception. 2018 Apr;97(4):287-291. doi: 10.1016/j.contraception.2017.09.016. Epub 2017 Oct 11.

15.

Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma.

Bouattour M, Raymond E, Qin S, Cheng AL, Stammberger U, Locatelli G, Faivre S.

Hepatology. 2018 Mar;67(3):1132-1149. doi: 10.1002/hep.29496. Epub 2018 Feb 1. Review.

16.

Generation and functional characterization of anti-human and anti-mouse IL-36R antagonist monoclonal antibodies.

Ganesan R, Raymond EL, Mennerich D, Woska JR Jr, Caviness G, Grimaldi C, Ahlberg J, Perez R, Roberts S, Yang D, Jerath K, Truncali K, Frego L, Sepulveda E, Gupta P, Brown SE, Howell MD, Canada KA, Kroe-Barrett R, Fine JS, Singh S, Mbow ML.

MAbs. 2017 Oct;9(7):1143-1154. doi: 10.1080/19420862.2017.1353853. Epub 2017 Jul 20.

17.

Physiological and pathophysiological control of synaptic GluN2B-NMDA receptors by the C-terminal domain of amyloid precursor protein.

Pousinha PA, Mouska X, Raymond EF, Gwizdek C, Dhib G, Poupon G, Zaragosi LE, Giudici C, Bethus I, Pacary E, Willem M, Marie H.

Elife. 2017 Jul 6;6. pii: e25659. doi: 10.7554/eLife.25659.

18.

Optimum Tools for Predicting Clinical Outcomes in Prostate Cancer Patients Undergoing Radical Prostatectomy: A Systematic Review of Prognostic Accuracy and Validity.

Campbell JM, Raymond E, O'Callaghan ME, Vincent AD, Beckmann KR, Roder D, Evans S, McNeil J, Millar J, Zalcberg J, Borg M, Moretti KL.

Clin Genitourin Cancer. 2017 Oct;15(5):e827-e834. doi: 10.1016/j.clgc.2017.06.001. Epub 2017 Jun 8. Review.

PMID:
28666689
19.

Tools for predicting patient-reported outcomes in prostate cancer patients undergoing radical prostatectomy: a systematic review of prognostic accuracy and validity.

O'Callaghan ME, Raymond E, Campbell J, Vincent AD, Beckmann K, Roder D, Evans S, McNeil J, Millar J, Zalcberg J, Borg M, Moretti K.

Prostate Cancer Prostatic Dis. 2017 Dec;20(4):378-388. doi: 10.1038/pcan.2017.28. Epub 2017 Jun 6. Review.

PMID:
28585573
20.

Tools for Predicting Clinical and Patient-reported Outcomes in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy: A Systematic Review of Prognostic Accuracy and Validity.

Campbell JM, O'Callaghan ME, Raymond E, Vincent AD, Beckmann KR, Roder D, Evans S, McNeil J, Millar J, Zalcberg J, Borg M, Moretti KL.

Clin Genitourin Cancer. 2017 Dec;15(6):629-634.e8. doi: 10.1016/j.clgc.2017.03.011. Epub 2017 Mar 30. Review.

PMID:
28576416
21.

Patient-Reported Outcomes After Radiation Therapy in Men With Prostate Cancer: A Systematic Review of Prognostic Tool Accuracy and Validity.

O'Callaghan ME, Raymond E, Campbell JM, Vincent AD, Beckmann K, Roder D, Evans S, McNeil J, Millar J, Zalcberg J, Borg M, Moretti K.

Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):318-337. doi: 10.1016/j.ijrobp.2017.02.024. Epub 2017 Feb 21. Review.

PMID:
28463151
22.

An appraisal of analytical tools used in predicting clinical outcomes following radiation therapy treatment of men with prostate cancer: a systematic review.

Raymond E, O'Callaghan ME, Campbell J, Vincent AD, Beckmann K, Roder D, Evans S, McNeil J, Millar J, Zalcberg J, Borg M, Moretti K.

Radiat Oncol. 2017 Mar 21;12(1):56. doi: 10.1186/s13014-017-0786-z. Review.

23.

Understanding c-MET signalling in squamous cell carcinoma of the head & neck.

Szturz P, Raymond E, Abitbol C, Albert S, de Gramont A, Faivre S.

Crit Rev Oncol Hematol. 2017 Mar;111:39-51. doi: 10.1016/j.critrevonc.2017.01.004. Epub 2017 Jan 12. Review.

PMID:
28259294
24.

Sixteen Years of Overregulation: Time to Unburden Mifeprex.

Mifeprex REMS Study Group, Raymond EG, Blanchard K, Blumenthal PD, Cleland K, Foster AM, Gold M, Grossman D, Pendergast MK, Westhoff CL, Winikoff B.

N Engl J Med. 2017 Feb 23;376(8):790-794. doi: 10.1056/NEJMsb1612526. No abstract available.

PMID:
28225670
25.

Novel TGF-β inhibitors ready for prime time in onco-immunology.

de Gramont A, Faivre S, Raymond E.

Oncoimmunology. 2016 Dec 7;6(1):e1257453. doi: 10.1080/2162402X.2016.1257453. eCollection 2017. Review.

26.

Serial multilevel urine pregnancy testing to assess medical abortion outcome: a meta-analysis.

Raymond EG, Shochet T, Blum J, Sheldon WR, Platais I, Bracken H, Dabash R, Weaver MA, Ngoc NTN, Blumenthal PD, Winikoff B.

Contraception. 2017 May;95(5):442-448. doi: 10.1016/j.contraception.2016.12.004. Epub 2016 Dec 29.

PMID:
28041991
27.

Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial.

Vinik A, Bottomley A, Korytowsky B, Bang YJ, Raoul JL, Valle JW, Metrakos P, Hörsch D, Mundayat R, Reisman A, Wang Z, Chao RC, Raymond E.

Target Oncol. 2016 Dec;11(6):815-824.

PMID:
27924459
28.

Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I study.

Coriat R, Faivre SJ, Mir O, Dreyer C, Ropert S, Bouattour M, Desjardins R, Goldwasser F, Raymond E.

Int J Nanomedicine. 2016 Nov 21;11:6207-6216. eCollection 2016.

29.

Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study.

Faivre S, Niccoli P, Castellano D, Valle JW, Hammel P, Raoul JL, Vinik A, Van Cutsem E, Bang YJ, Lee SH, Borbath I, Lombard-Bohas C, Metrakos P, Smith D, Chen JS, Ruszniewski P, Seitz JF, Patyna S, Lu DR, Ishak KJ, Raymond E.

Ann Oncol. 2017 Feb 1;28(2):339-343. doi: 10.1093/annonc/mdw561.

PMID:
27836885
30.

OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations.

Riveiro ME, Astorgues-Xerri L, Vazquez R, Frapolli R, Kwee I, Rinaldi A, Odore E, Rezai K, Bekradda M, Inghirami G, D'Incalci M, Noel K, Cvitkovic E, Raymond E, Bertoni F.

Oncotarget. 2016 Dec 20;7(51):84675-84687. doi: 10.18632/oncotarget.13181.

31.

N-Arylsulfonyl-α-amino carboxamides are potent and selective inhibitors of the chemokine receptor CCR10 that show efficacy in the murine DNFB model of contact hypersensitivity.

Abeywardane A, Caviness G, Choi Y, Cogan D, Gao A, Goldberg D, Heim-Riether A, Jeanfavre D, Klein E, Kowalski JA, Mao W, Miller C, Moss N, Ramsden P, Raymond E, Skow D, Smith-Keenan L, Snow RJ, Wu F, Wu JP, Yu Y.

Bioorg Med Chem Lett. 2016 Nov 1;26(21):5277-5283. doi: 10.1016/j.bmcl.2016.09.047. Epub 2016 Sep 21.

32.

Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor.

Kaye J, Piryatinsky V, Birnberg T, Hingaly T, Raymond E, Kashi R, Amit-Romach E, Caballero IS, Towfic F, Ator MA, Rubinstein E, Laifenfeld D, Orbach A, Shinar D, Marantz Y, Grossman I, Knappertz V, Hayden MR, Laufer R.

Proc Natl Acad Sci U S A. 2016 Oct 11;113(41):E6145-E6152. Epub 2016 Sep 26.

33.

Effects of Depot Medroxyprogesterone Acetate Injection Timing on Medical Abortion Efficacy and Repeat Pregnancy: A Randomized Controlled Trial.

Raymond EG, Weaver MA, Louie KS, Tan YL, Bousiéguez M, Aranguré-Peraza AG, Lugo-Hernández EM, Sanhueza P, Goldberg AB, Culwell KR, Kaplan C, Memmel L, Sonalkar S, Jamshidi R, Winikoff B.

Obstet Gynecol. 2016 Oct;128(4):739-45. doi: 10.1097/AOG.0000000000001627.

PMID:
27607859
34.

Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib.

Serova M, Tijeras-Raballand A, Dos Santos C, Martinet M, Neuzillet C, Lopez A, Mitchell DC, Bryan BA, Gapihan G, Janin A, Bousquet G, Riveiro ME, Bieche I, Faivre S, Raymond E, de Gramont A.

Oncotarget. 2016 Jun 21;7(25):38467-86. doi: 10.18632/oncotarget.9542.

35.

Efficacy of a sequential treatment strategy with GEMOX-based followed by FOLFIRI-based chemotherapy in advanced biliary tract cancers.

Sebbagh S, Roux J, Dreyer C, Neuzillet C, de Gramont A, Orbegoso C, Hentic O, Hammel P, de Gramont A, Raymond E, André T, Chibaudel B, Faivre S.

Acta Oncol. 2016 Sep - Oct;55(9-10):1168-1174. doi: 10.1080/0284186X.2016.1191670. Epub 2016 Jun 22.

PMID:
27333436
36.

Structural and Functional Attributes of the Interleukin-36 Receptor.

Yi G, Ybe JA, Saha SS, Caviness G, Raymond E, Ganesan R, Mbow ML, Kao CC.

J Biol Chem. 2016 Aug 5;291(32):16597-609. doi: 10.1074/jbc.M116.723064. Epub 2016 Jun 15.

37.

c-MET-mediated resistance to EGFR inhibitors in head and neck cancer: How to move from bench to bedside.

Szturz P, Raymond E, Faivre S.

Oral Oncol. 2016 Aug;59:e12-e14. doi: 10.1016/j.oraloncology.2016.05.017. Epub 2016 Jun 11. No abstract available.

PMID:
27302885
38.

Noninvasive Longitudinal Study of a Magnetic Resonance Imaging Biomarker for the Quantification of Colon Inflammation in a Mouse Model of Colitis.

Bianchi A, Bluhmki T, Schönberger T, Kaaru E, Beltzer A, Raymond E, Wunder A, Thakker P, Stierstorfer B, Stiller D.

Inflamm Bowel Dis. 2016 Jun;22(6):1286-95. doi: 10.1097/MIB.0000000000000755.

PMID:
27104818
39.

Increasing Access to Abortion With Telemedicine.

Raymond EG, Chong E, Hyland P.

JAMA Intern Med. 2016 May 1;176(5):585-6. doi: 10.1001/jamainternmed.2016.0573. No abstract available.

PMID:
27019353
40.

Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib?

Faivre S, de Gramont A, Raymond E.

Target Oncol. 2016 Aug;11(4):565-7. doi: 10.1007/s11523-016-0427-8. No abstract available.

PMID:
26996978
41.

Effect of Immediate Compared With Delayed Insertion of Etonogestrel Implants on Medical Abortion Efficacy and Repeat Pregnancy: A Randomized Controlled Trial.

Raymond EG, Weaver MA, Tan YL, Louie KS, Bousiéguez M, Lugo-Hernández EM, Aranguré-Peraza AG, Sanhueza P, Kaplan C, Sonalkar S, Goldberg AB, Culwell KR, Memmel L, Jamshidi R, Winikoff B.

Obstet Gynecol. 2016 Feb;127(2):306-12. doi: 10.1097/AOG.0000000000001274.

PMID:
26942358
42.

ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas.

Garcia-Carbonero R, Sorbye H, Baudin E, Raymond E, Wiedenmann B, Niederle B, Sedlackova E, Toumpanakis C, Anlauf M, Cwikla JB, Caplin M, O'Toole D, Perren A; Vienna Consensus Conference participants.

Neuroendocrinology. 2016;103(2):186-94. doi: 10.1159/000443172. Epub 2016 Jan 5. No abstract available.

43.

Contemporary reviews on cancer treatment.

Peters GJ, Raymond E.

Cancer Chemother Pharmacol. 2016 Jan;77(1):3-4. doi: 10.1007/s00280-015-2943-0. No abstract available.

PMID:
26703128
44.

Social participation at the intersection of old age and lifelong disability: Illustrations from a Photo-Novel Project.

Raymond É, Grenier A.

J Aging Stud. 2015 Dec;35:190-200. doi: 10.1016/j.jaging.2015.08.001. Epub 2015 Oct 2. No abstract available.

PMID:
26568228
45.

Comparison of impact forces, accelerations and ankle range of motion in surfing-related landing tasks.

Lundgren LE, Tran TT, Nimphius S, Raymond E, Secomb JL, Farley OR, Newton RU, Sheppard JM.

J Sports Sci. 2016;34(11):1051-7. doi: 10.1080/02640414.2015.1088164. Epub 2015 Sep 18.

PMID:
26383823
46.

Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors.

Faivre SJ, Olszanski AJ, Weigang-Köhler K, Riess H, Cohen RB, Wang X, Myrand SP, Wickremsinhe ER, Horn CL, Ouyang H, Callies S, Benhadji KA, Raymond E.

Invest New Drugs. 2015 Dec;33(6):1206-16. doi: 10.1007/s10637-015-0286-7. Epub 2015 Sep 16.

PMID:
26377590
47.

Enhancing the protein resistance of silicone via surface-restructuring PEO-silane amphiphiles with variable PEO length.

Rufin MA, Gruetzner JA, Hurley MJ, Hawkins ML, Raymond ES, Raymond JE, Grunlan MA.

J Mater Chem B. 2015 Apr 14;3(14):2816-2825.

48.

Signal Transduction and Intracellular Trafficking by the Interleukin 36 Receptor.

Saha SS, Singh D, Raymond EL, Ganesan R, Caviness G, Grimaldi C, Woska JR Jr, Mennerich D, Brown SE, Mbow ML, Kao CC.

J Biol Chem. 2015 Sep 25;290(39):23997-4006. doi: 10.1074/jbc.M115.653378. Epub 2015 Aug 12.

49.

Methylome sequencing for fibrolamellar hepatocellular carcinoma depicts distinctive features.

Malouf GG, Tahara T, Paradis V, Fabre M, Guettier C, Yamazaki J, Long H, Lu Y, Raynal NJ, Jelinek J, Mouawad R, Khayat D, Brugières L, Raymond E, Issa JP.

Epigenetics. 2015;10(9):872-81. doi: 10.1080/15592294.2015.1076955.

50.

Targeting cancer cell metabolism in pancreatic adenocarcinoma.

Cohen R, Neuzillet C, Tijeras-Raballand A, Faivre S, de Gramont A, Raymond E.

Oncotarget. 2015 Jul 10;6(19):16832-47. Review.

Supplemental Content

Loading ...
Support Center